TAXUS V:A Randomized Double-blind Trial to Access TAXUS Paclitaxel-eluting Coronary Stents, Slow Release Formulation, in the Treatment of High Risk de novo Coronary Lesions
Study of:
TAXUS-SR Paclitaxel coated stent vs. an uncoated bare metal stent; sponsored by Boston Scientific SCIMED
Drug coated or drug eluting stents are designed to block excessive cell growth that can cause restenosis (renarrowing of the artery) after stent implantation. Restenosis can occur in about 25% of the patients who receive a coronary artery stent. Drug coated stents are currently being studied to reduce the growth of scar tissue in the coronary artery.
The TAXUS V study is to evaluate the TAXUS-SR Paclitaxel coated stent vs. an uncoated bare metal stent in patients who have new coronary disease in one or two vessels. All patients who consent to the trial will return at 9 months for a follow-up angiogram. Paclitaxel is the active ingredient in Taxol®, a drug developed to treat cancer. The addition of the paclitaxel coating could possibly improve the performance of the stent by preventing the re-narrowing of the treated coronary vessel.
- M. Nicholas Burke, MD
- Ivan J. Chavez, MD, FACC
- Timothy D. Henry, MD, FACC
- John R. Lesser, MD, FACC
- Daniel Lips, MD, FACC
- James D. Madison, MD, FACC
- Wesley R. Pedersen, MD, FACC
- Anil K. Poulose, MD, FACC
- Jay H. Traverse, MD, FACC, FAHA
- Yale Wang, MD, FACC, FSCAI
For more information about the interventional cardiology research program at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124. |